Scienture Granted Third USPTO Patent For Arbli Oral Solution In Treating Hypertension

May 06, 2026 — 11:37 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Scienture Holdings Inc. (SCNX), a holding company for pharmaceutical companies, announced on Wednesday a third patent for the Arbli oral suspension or Losartan potassium in treating hypertension, granted by the U.S. patent and trademark office or USPTO.

Arbli is an angiotensin receptor blocker or ARB, formulated as an oral suspension for administration to pediatric and geriatric patients, and other patient populations facing difficulties in swallowing. It is the first oral liquid suspension for the treatment of hypertension and was approved in March 2025 by the U.S. food and drug administration.

The patent was granted on April 21 and will provide intellectual property protection and market exclusivity till October 7, 2041.

SCNX is trading at $0.41, up 5.54%.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Scienture Granted Third USPTO Patent For Arbli Oral Solution In Treating Hypertension

Tags

Latest Articles